TCRG Cannaisseur Group Inc.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1879270 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY78.2%
TTM EPS YoY100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-162,372.1%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets2,151,675.0%
Debt / equity—
Current ratio0.00x
Interest coverage-403.02x
Cash quality & payout
Operating cash flow / net income0.28x
Accruals ratio-116,771.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $118 | $0 | $192 | $272 | $282 | $164 | $1,113 |
| Gross profit | $0 | -$118 | $0 | -$192 | -$272 | -$282 | -$164 | -$1,113 |
| SG&A expense | $85,191 | $94,708 | $102,257 | $101,211 | $690,209 | $77,207 | $846,908 | $88,274 |
| Operating income | -$85,191 | -$94,826 | -$102,257 | -$101,403 | -$690,481 | -$77,489 | -$847,072 | -$89,387 |
| Interest expense | $237 | $237 | $238 | $240 | $686 | $1,640 | $1,711 | $1,701 |
| Pretax income | -$85,428 | -$95,063 | -$102,495 | -$101,643 | -$778,824 | -$79,129 | -$848,783 | -$91,088 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$85,312 | -$94,889 | -$102,378 | -$101,431 | -$745,167 | -$78,732 | -$848,583 | -$90,433 |
| EBITDA | — | — | — | — | — | — | — | -$89,387 |
| EPS (basic) | 0.00 | 0.00 | 0.00 | — | -0.01 | 0.00 | -0.02 | — |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | — | -0.01 | 0.00 | -0.02 | — |
| Weighted avg. shares (diluted) | 60.46M | 60.46M | 60.45M | — | 57.18M | 49.91M | 47.88M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $20 | $41 | $45 | $22 | $143 | $2,558 | $20,400 | $563 |
| Receivables | — | — | — | $0 | $0 | $0 | $285 | $285 |
| Inventory | $0 | $0 | $118 | $118 | $310 | $582 | $864 | $1,028 |
| Current assets | $20 | $41 | $163 | $140 | $453 | $3,140 | $21,549 | $1,876 |
| Total assets | $20 | $41 | $163 | $140 | $453 | $3,140 | $21,549 | $1,876 |
| Current liabilities | $406,051 | $338,278 | $273,580 | $210,632 | $128,894 | $408,164 | $347,733 | $229,113 |
| Total liabilities | $430,335 | $362,735 | $298,209 | $235,431 | $153,861 | $433,298 | $384,032 | $305,576 |
| Shareholders' equity | -$287,506 | -$220,001 | -$155,527 | -$92,889 | -$11,218 | -$359,500 | -$292,222 | -$233,639 |
| Shares outstanding | 60.46M | 60.46M | 60.46M | 60.46M | 60.46M | 49.76M | 49.98M | 44.34M |
| Cash flow statement | ||||||||
| Operating cash flow | -$17,828 | -$30,419 | -$39,717 | -$19,881 | -$21,065 | -$17,842 | -$68,663 | -$12,469 |
| Financing cash flow | $17,807 | $30,415 | $39,740 | $19,760 | $18,650 | $0 | $88,500 | $12,500 |
| Depreciation & amortization | — | — | — | — | — | — | — | $0 |
| Stock-based compensation | $0 | $0 | $0 | $0 | $592,962 | $0 | $700,000 | $0 |
Free plan shows the latest 8 periods; Pro shows all 19 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.